This was a phase IIa, randomised, double-blind study assessing the safety and efficacy of a potential new asthma treatment, in patients with uncontrolled, moderate-to-severe, persistent asthma.
Approximately 194 subjects were enrolled over a number of centres in Bulgaria, Germany, Poland, Romania and the UK. Subjects were randomised to one of three treatment arms to receive subcutaneous treatment of the study medication.
The primary objective of this study was to evaluate the effect of the study medication on asthma control against placebo. Other objectives included safety, time to asthma control, asthma exacerbation rate and severity, and time to first asthma exacerbation.
Illingworth research were responsible for study management and monitoring in the UK.